<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>1850</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>101</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-12-18</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2023-09-11</thesisDateAccepted>
    <title language="eng">Targeted therapy to overcome the blood-brain barrier in treating Glioblastoma</title>
    <abstract language="eng">Glioblastoma represents a challenge in oncology, characterized by its aggressive nature and resistance to conventional therapies. This thesis conducts a comprehensive examination of Glioblastoma, with a primary focus on advancing therapeutic strategies through precision medicine and sophisticated drug delivery mechanisms. The inquiry starts with an exhaustive analysis of the intricate blood-brain barrier, a vital neurovascular interface critical for understanding drug delivery complexities to the central nervous system. Subsequently, the study delves into Glioblastoma, elucidating its etiological foundations, molecular intricacies, clinical presentations, and existing treatment paradigms.&#13;
The core of this research centers on the exploration of state-of-the-art targeted therapies, encompassing molecular-level targeting, immunotherapeutic modalities, and synergistic therapeutic approaches. It dissects a range of strategies aimed at enhancing drug delivery, including chemical disruption techniques, innovative delivery methodologies, and bioengineered approaches.&#13;
Furthermore, it underscores the transformative potential of nanotechnology, emphasizing nanocarriers as precision tools poised to revolutionize GBM therapy.&#13;
The literature review is conducted meticulously, drawing from renowned databases like PubMed, NCBI, NIH/National Cancer Institute, JSTOR, and BioMed Central. Additionally, reputable national and international health institute websites, along with carefully selected books from the campus library, contribute to the diverse and robust foundation of credible information.&#13;
The discussion segment dissects the challenges inherent in GBM targeted treatment, underscores the burgeoning domain of precision medicine, highlights the paradigm-shifting role of theranostics,&#13;
and outlines a roadmap for future prospects in this intricate landscape.</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-18504</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>CC BY-NC-ND 4.0 International - Namensnennung-Nicht kommerziell-Keine Bearbeitungen</licence>
    <author>Fatma Belkhodja</author>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1850/Belkhodja.BSc.thesis.pdf</file>
  </doc>
  <doc>
    <id>1814</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>99</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-10-03</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2023-09-15</thesisDateAccepted>
    <title language="eng">The use of biocatalysis in the diagnosis and treatment of colorectal cancer (CRC)</title>
    <abstract language="eng">Colorectal cancer is a significant global health burden. Early-stage colorectal cancer is asymptomatic, which, coupled with the fact that later stages of CRC have a very low prognosis, and that current methods of diagnosis and treatment significantly impact the patient, exploring alternate ways to diagnose and treat CRC is vital.&#13;
Biocatalysis is the use of naturally found catalysts such as nanozymes and enzymes in order to catalyze reactions. Due to their characteristics and uses, biocatalysts are seen as promising alternatives to current methods of CRC diagnosis and therapy.&#13;
This research-based bachelor thesis aims to summarize and analyze current traditional and biocatalytic methods that exist to diagnose and treat CRC, in order to seek the potential of biocatalysis in this field, as well as discuss its current state and its future in comparison to currently implemented methods. It provides an extensive overview of traditional and biocatalytic approaches to diagnosis and therapy, considering important factors such as efficacy, sensitivity, selectivity, cost, and safety.&#13;
The thesis also delves into the use of biocatalysis for important points such as the early diagnosis of CRC, and the challenges faced during development, regulation, and monetary concerns. Through careful analysis of the strengths and limitations of techniques in the field, as well as personal opinions on the future of research, conclusions on given hypotheses regarding biocatalysis in CRC diagnosis and therapies were presented and included strong support for the unquestionable potential of biocatalysis use in cancer healthcare, while highlighting possibilities to tap into that potential by scrutinizing their equally as unquestionable current limitations.&#13;
Overall, this thesis aspires to contribute, on however minuscule a scale, towards the advancement of CRC diagnosis and therapy approaches, with the ambition of improving patient care and prognosis, as well as quality of life for those struggling or who will struggle in the future with the disease, together with their kin who are profoundly affected as well.</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-18147</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>CC BY-NC-ND 4.0 International - Namensnennung-Nicht kommerziell-Keine Bearbeitungen</licence>
    <author>Basil Mazen Hammoudeh</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Colorectal cancer</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Cancer</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Biocatalysis</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Enzymes</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Diagnosis</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Therapy</value>
    </subject>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1814/BasilHammoudeh_Thesis_FINAL_SIGNED.pdf</file>
  </doc>
  <doc>
    <id>1796</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber/>
    <edition/>
    <issue/>
    <volume/>
    <type>masterthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-08-28</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2023-08-21</thesisDateAccepted>
    <title language="eng">The Use of Pig insulin and Grafts in the treatment of Human Diabetes</title>
    <abstract language="eng">Biological resources are entities of natural origin with sources from either plants or animals that render a broad number of services to mankind. Purified pig insulin, pancreas, islet, and beta cells are biological resources synthesized, extracted, and isolated from pigs to provide medical services like treating human diabetes. &#13;
The observed methodology was obtained by systematically reviewing and comparing other similar scientific studies to determine the challenges and risks associated with using pig grafts (islet, pancreas, beta cells) for the treatment of type 1 diabetes (T1D), the optimal pig age for extracting graft for treatment of diabetes, differences between human and pig insulin, and the clinical trials and adoption pig insulin and graft therapies for type 1 diabetes treatment.&#13;
Xenotransplantation of pig grafts has successfully restored normoglycemia in a Type 1 diabetes patient for about 9.5 years, thus potentially being an alternative therapy to human islet allotransplantation. However, the clinical adoption of using &#13;
pig grafts for diabetes treatment is hindered by the unavailability of T1D volunteers to be used for clinical trials because of risks like zoonosis, loss of body weight, immunosuppression, and death of the transplanted pig implant.&#13;
Xenotransplantation of pig grafts to T1D can be clinically accepted through advanced practices like Genetic modifications of the pig, encapsulating the pig grafts before transplantation, and co-transplantation of the pig grafts with Mesenchymal Stem Cell (MSCs) and/or Sertoli cells (SCs). The clinical adoption of pig grafts for T1D treatment will mitigate the problem of limited islet/pancreas &#13;
donor sources encountered in allotransplantation, hence more research and studies are needed for this milestone to be accomplished.</abstract>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>CC0 1.0 Universell - Gemeinfreiheit (Public Domain)</licence>
    <author>Somtoo Dominic Okolie</author>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
  </doc>
  <doc>
    <id>1944</id>
    <completedYear/>
    <publishedYear>2024</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>78</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2024-05-06</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2024-04-08</thesisDateAccepted>
    <title language="eng">Efficacy of Traditional Chinese Medical DrugsThe Treatment of Common Illnesses in Comparison with Western medicine</title>
    <abstract language="eng">The efficacy of treating common illnesses with traditional Chinese medical drugs has been a subject of growing interest and debate especially when compared to established practices of modern &#13;
Western medicine. The integration of alternative and traditional medicine practices also gains significance as healthcare systems evolve. &#13;
This literature review aims to comprehensively assess and compare the effectiveness of traditional Chinese medical drugs with modern Western medial drugs in addressing common illnesses. Through a systematic analysis of reviewed scientific articles, clinical studies, and relevant literature the effectiveness of traditional Chinese medical drugs will be identified and compared to modern Western medical drugs and treatment options in context of the treatment success rates, symptom relief, adverse effects, and patient satisfaction.&#13;
The study focuses on the herbal based remedies and their traditional therapeutic treatment methods, to illuminate their mechanisms of action and potential therapeutic benefits for a range of common illnesses such as the common cold and flu, digestive disorders, musculoskeletal pain, and skin conditions. Furthermore, the potential synergies between the two practices will be explored, as integrative healthcare becomes increasingly important as a comprehensive approach to patient wellbeing.&#13;
Through a comprehensive analysis of the available medical literature and clinical data, this paper attempts to address the potential of traditional Chinese medical drugs as an alternative or complementary method to modern Western medicine for various common illnesses. The findings may contribute to informed decision-making by healthcare professionals and patients, offering insights into the strengths and limitations of each approach. Additionally, the research aims to foster a deeper understanding of cross-cultural medical practices and their potential integration into contemporary healthcare systems.</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-19440</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>CC BY-NC-ND 4.0 International - Namensnennung-Nicht kommerziell-Keine Bearbeitungen</licence>
    <author>Clarissa May</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Traditional Chinese medicine</value>
    </subject>
    <collection role="ddc" number="61">Medizin und Gesundheit</collection>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1944/May_Clarissa_Bachelorarbeit.pdf</file>
  </doc>
  <doc>
    <id>469</id>
    <completedYear/>
    <publishedYear>2020</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber/>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2020-06-10</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2020-05-19</thesisDateAccepted>
    <title language="eng">Evolution of CRISPR-Cas genome editing methods: Chances and challenges in biotechnology</title>
    <abstract language="eng">Clustered regularly interspaced short palindromic repeats, CRISPR, are located on DNA sequences, which encode for an antiviral defense mechanism in bacteria and archaea. Together with CRISPR-associated proteins, Cas endonucleases, CRISPR-Cas has emerged into a powerful platform for editing DNA and RNA. This thesis investigates the evolution and function of this prokaryotic defense mechanism and points out the three most applied CRISPR-Cas systems in relation to current applications in biotechnology. Furthermore, chances and challenges of named systems as well as a guideline for choosing the appropriate system with Cas endonucleases is framed. Therefore, several scientific databases were screened for the most informative and influential publications around the topic. Information was collected and organized in a reference management software. The utilized literature was tabularly denoted and gives an overview of the broad scope of CRISPR-Cas. The analysis of the topic shows, that CRISPR-Cas offers a broad application range with a huge chance for genome editing. A conclusion of this thesis is, that CRISPR-Cas has an enormous potential to be implemented for human genome editing. However, its challenges should be cleared beforehand. Further research has to be done to fully understand the impact CRISPR-Cas may have in future.</abstract>
    <licence>CC BY-NC-ND 4.0 International - Namensnennung-Nicht kommerziell-Keine Bearbeitungen</licence>
    <author>Lara Khedher</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Genome editing</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Genetics</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>CRISPR</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Cas</value>
    </subject>
    <collection role="ddc" number="50">Naturwissenschaften</collection>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
  </doc>
  <doc>
    <id>1608</id>
    <completedYear/>
    <publishedYear>2022</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>88</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2022-10-26</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2022-07-20</thesisDateAccepted>
    <title language="eng">CRISPR technology in human medicine: advantages and disadvantages over traditional treatments</title>
    <abstract language="eng">Genome editing tools hold tremendous potential in fighting various diseases via editing specific sites within the target gene of interest of distinct cell types. Among these tools, CRISPR has shown several advantages over alternative nucleases, such as ease of design, high efficiency, and low cost. In this work, a comprehensive review of the existing research on the application of CRISPR technology to the treatment of human diseases is presented. These diseases include monogenic and infectious diseases, as well as conditions for which immunotherapies are typically applied, such as cancer and autoimmune disorders. Following this review is an analysis of the advantages and disadvantages of CRISPR-based strategies compared to traditional treatments in a selection of diseases; this aims to demonstrate the overall potential of CRISPR therapeutic applications in humans and the need for further investigation and development.</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-16080</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>CC BY 4.0 International - Namensnennung</licence>
    <author>Mahmoud Karssli</author>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1608/Karssli_Thesis.pdf</file>
  </doc>
  <doc>
    <id>1530</id>
    <completedYear/>
    <publishedYear>2022</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>72</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2022-06-29</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2022-06-06</thesisDateAccepted>
    <title language="eng">Comparative analysis of guide RNA design tools</title>
    <abstract language="eng">Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR), has rapidly come to the forefront of genome engineering and has revolutionized the field. Today, CRISPR-Cas is regarded to be the most effective and efficient tool in genome editing. It is considered to have many applications in medicine, agriculture and biotechnology. The Cas protein and gRNA are two of the most crucial components of the CRISPR-Cas system. Currently, there are barriers that prevent the full potential of CRISPR-Cas systems in clinical applications, including, ethical concerns, off-target effects, immune system response, method of delivery. Off-target prevention relies heavily on gRNA analysis. With the help of technology and algorithms developed based on researches, there have been many bioinformatical tools focused on the off-target activity inhibition and increasing efficiency. In order to achieve practical use of CRISPR systems, there needs to be more predictive bioinformatical tools to minimize the off-target activity. This thesis aims to review some of these tools and discusses the criteria for future bioinformatical tools’ development by addressing the current limitations and challenges.&#13;
This thesis is written theoretically by using various reputable resources such as PubMed in English. Because many of the tools covered in this thesis had no prior reviews, the author had to learn how to use them, therefore this thesis does not cover all of their features for professional users.&#13;
In the result section, the author has provided figures from the interface of the tools along with description of the functionality of the algorithms in use. All of the mentioned tools are then examined in the discussion part. There, features such as speed, ease of use for beginners, price, being open-source, being web or local based, flexibility in working with other tools and batch analysis are reviewed and compared. There short conclusive results are also depicted in a table for effective comparison.</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-15307</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>CC BY-NC-SA 4.0 International - Namensnennung-Nicht kommerziell-Weitergabe unter gleichen Bedingungen</licence>
    <author>Parsa Lavasanifar</author>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1530/Thesis.pdf</file>
  </doc>
  <doc>
    <id>1532</id>
    <completedYear/>
    <publishedYear>2022</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>83</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2022-06-30</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2022-04-18</thesisDateAccepted>
    <title language="eng">Significance of gut microbiota in prognosis of cancer therapy-induced rectal mucositis and treatment outcome</title>
    <abstract language="eng">Colorectal cancer is a common type of cancer. Chemotherapy is an important method to treat cancer. 5-fluorouracil (5-FU) is a commonly used drug in chemotherapy regimens. 5-FU not only inhibited cancer cell division but also accelerated the apoptosis of intestinal epithelial cells. lead to colorectal mucositis. Some patients will develop severe mucositis, making subsequent treatment difficult and even life-threatening. The role of gut microbiota in the process of 5-FU-induced colorectal mucositis, and the regulation of gut microbiota through dietary regimens to reduce the possibility of colorectal mucositis deterioration are the research directions of this thesis. This thesis uses PubMed, NCBI and textbooks as the main reference sources, and some information comes from trusted websites. Through review and integration of research, it was concluded that gut microbiota played a non-negligible role in 5-FU-induced colorectal mucositis. Probiotics help maintain the stability of the intestinal mucosal barrier. The main cause of colorectal mucositis is that 5-FU suppresses the immune system and disrupts the immune system. Under the influence of 5-FU, intestinal flora dysbiosis occurs, and the intestinal mucosal barrier function is negatively affected. This leads to the worsening of colorectal mucositis. It can be inferred from research that a reasonable dietary regimen can reduce the possibility of exacerbation of colorectal mucositis. Furthermore, the digestive tract should be viewed as a whole. The role of the stomach and small intestine in the process of 5-FU-induced colorectal mucositis still needs further study. The research of gut microbes in this thesis focuses on Bifidobacterium and Lactobacillus. Pathogenic/opportunistic pathogens and other probiotics are understudied. More in-depth studies are still needed on the role of gut microbes in the process of 5-FU-induced colorectal mucositis</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-15323</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>CC BY 4.0 International - Namensnennung</licence>
    <author>Ziang Wu</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Colorectal mucositis</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Micobiota</value>
    </subject>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1532/Wu_Bioengineering.pdf</file>
  </doc>
  <doc>
    <id>1537</id>
    <completedYear/>
    <publishedYear>2022</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>92</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2022-07-03</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2022-05-10</thesisDateAccepted>
    <title language="eng">3D bioprinting of cartilage tissue: Current advances and challenges in tissue engineering</title>
    <abstract language="eng">As industrial technologies develop, some techniques were adopted and applied in medical fields for treatment improvement. Among them, 3D bioprinting is regarded as a rising and trending technology in the tissue engineering area. This is because not only does it offer patients customized organs or tissues, but also it can lower animal test dependency on drug testing. This paper is mainly focused on the use of 3D printing as a cartilage tissue fabrication for transplantation. In the beginning, general information and background knowledge concerning cartilage and bioprinting approaches were addressed. Subsequently, current research results from eight research teams related to cartilage tissue printing and grafting were introduced. Then the reports were classified and sorted into several groups to analyze and evaluate various methods' properties, advantages, and disadvantages. After that, some classic and traditional ways to produce artificial tissues without 3D bioprinting techniques were described to prove the strength of the novel tissue engineering technology. In the end, several side points, such as limitations, 3D bioprinting usages in fields other than tissue transplantation, market value, and outlook of bioprinting, were discussed. Information and sources were retrieved using Google and PubMed database search engines under specific inclusion and exclusion criteria through a PCC concept. Although the 3D bioprinting technique is still in development processes, it has a high potential to be a game-changing approach in the medical and pharmaceutical fields after commercialization in the future.</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-15373</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>CC BY-NC-ND 4.0 International - Namensnennung-Nicht kommerziell-Keine Bearbeitungen</licence>
    <author>Wooyong Kim</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>3D bioprinting</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Cartilage</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Tissue transplantation</value>
    </subject>
    <collection role="ddc" number="50">Naturwissenschaften</collection>
    <collection role="ddc" number="61">Medizin und Gesundheit</collection>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1537/Kim_Wooyong_Bachelorthesis.pdf</file>
  </doc>
  <doc>
    <id>1510</id>
    <completedYear/>
    <publishedYear>2021</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>91</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2022-05-30</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Oral Enzyme Therapy in Systemic Analgetic Treatment</title>
    <abstract language="eng">The possibility of an oral enzyme combination being able to replace diclofenac in the treatment of pain and inflammation is discussed. Oral enzyme therapy involves the use of proteolytic enzymes like bromelain, serratiopeptidase, trypsin, rutin, and papain. The goal of oral enzyme therapy is to replace non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of symptoms requiring short or long-term treatment due to the side effects of NSAIDs for example diclofenac. The main analysis is focused on the analgesic and anti-inflammatory effects of oral enzyme therapy.&#13;
The results are based on database retrieval covering single oral enzymes and oral enzyme combinations like Wobenzym and Phlogenzym. Osteoarthritis and post- surgery treatment studies of oral enzyme therapy are included to analyze the efficacy and effectiveness of the new treatment approach. Bromelain, serratiopeptidase, and rutin are covered in their industrial production. Safety and efficacy, trial diversity, economics, and the potential of oral enzymes being the new homeopathy are discussed.&#13;
Oral enzymes show a great safety profile in the overall comparison to NSAIDs with tolerability rated as good and very good by patients and physicians. The trial diversity has an impact on the comparability resulting in the need for a cohesion set-up for the retrieval of evidence on the efficacy and effectiveness of oral enzyme therapy. The economic situation of oral enzymes is defined by the currently expensive production of enzymes with a possible reduction in retail price due to new techniques and technology. With the presence of new studies of high quality in the future, a detailed revision of facts is advised on oral enzymes being an alternative to NSAIDs.</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-15107</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <licence>CC BY-NC-ND 4.0 International - Namensnennung-Nicht kommerziell-Keine Bearbeitungen</licence>
    <author>Lisa-Camilla Mutzberg</author>
    <subject>
      <language>deu</language>
      <type>uncontrolled</type>
      <value>Oral enzyme therapy</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>NSAIDs</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Proteolytic enzymes</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Diclofenac</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>Osteoarthritis</value>
    </subject>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1510/Lisa-Camilla_Mutzberg_25093.pdf</file>
  </doc>
  <doc>
    <id>1673</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>80</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-02-06</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>2022-12-27</thesisDateAccepted>
    <title language="eng">Evaluating the potential of mRNA vaccines for human rabies</title>
    <abstract language="eng">To this date, rabies is still one of the most fatal diseases worldwide and generates at least 59,000 deaths per year. Although current vaccines are safe and effective, RNA technology proposes improved vaccines that are potentially able to facilitate eradication of rabies until 2030. In this review, RNA vaccine candidates are evaluated for their potential to be effective against rabies and to be implemented in immunization programs. To understand the relevance of disease prevention, rabies virus and its function in the body is clarified. RNA technology is explained to comprehend its mode of action in the human immune system and its potential to be a vaccine platform. Comparison to existing vaccines showed advantages in several characteristics that are relevant for vaccine approval. RNA vaccines scored better in efficacy, stability, production, and dosing, but there is still room for improvements in terms of safety and tolerability. Theoretical potential is proven, but practical translation of RNA vaccines into clinical candidates requires more attention, as safety and tolerability are the leading limiting factor for approval of any new drug or vaccine. Producing a safe, stable and effective RNA vaccine does not necessarily ensure less rabies deaths, because rabies control strategies heavily rely on proper funding and availability in these rabies endemic region. Nonetheless, RNA vaccine technology offers potential solutions for the elimination of rabies.</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-16737</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>Bestimmungen des deutschen Urheberrechts</licence>
    <author>Ole Waller</author>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1673/Bachelorthesis_OWaller_25337.pdf</file>
  </doc>
  <doc>
    <id>1696</id>
    <completedYear/>
    <publishedYear>2023</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber>62</pageNumber>
    <edition/>
    <issue/>
    <volume/>
    <type>bachelorthesis</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2023-03-06</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">A Structured Classification and Evaluation of Current and Future Treatments for Systemic Lupus Erythematosus</title>
    <abstract language="eng">Systemic Lupus Erythematosus (SLE) is a heterogeneous autoimmune disease that has a variety of manifestations and is therefore difficult to find a treatment for. Several advances have occurred in the field of SLE drug discovery, especially since the publishing of the first Genome Wide-Associated Studies in 2005. More than one hundred loci were found to be involved in the disease. Subsequently, the treatments were aimed towards tackling the pathways that were found after the uses of modern genetic techniques. Historically, the FDA approved only two drugs for treatment until the approval of Belimumab in 2011. Ten years later, two more drugs were approved in the same year, with few more drugs expected to receive approval in the near future. This study aims to evaluate the efficacy of these future drugs in addition to the ones considered to be milestones in the treatment of SLE, finding Anifrolumab to be the most promising drug currently on the market for treatment of moderate to severe SLE and Obinutuzumab to be the drug to watch.</abstract>
    <identifier type="urn">urn:nbn:de:hbz:1383-opus4-16960</identifier>
    <enrichment key="opus.source">publish</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">true</enrichment>
    <licence>CC0 1.0 Universell - Gemeinfreiheit (Public Domain)</licence>
    <author>Ahmed Abdelazim</author>
    <collection role="institutes" number="">Fakultät Life Sciences</collection>
    <thesisPublisher>Hochschule Rhein-Waal</thesisPublisher>
    <thesisGrantor>Hochschule Rhein-Waal</thesisGrantor>
    <file>https://opus4.kobv.de/opus4-rhein-waal/files/1696/Abdelazim_Lupus.pdf</file>
  </doc>
</export-example>
